UY31984A - DERIVADOS DE 1-(3,4-difluorobencil)-6-oxo-1,6-dihidropirimidin-5-carboxamidas N-sustituidas y de 2-(3,4-difluorobencil)-3-oxo-2,3-dihidro-1H-pirazol-4-carboxamidas N-sustituidas. - Google Patents

DERIVADOS DE 1-(3,4-difluorobencil)-6-oxo-1,6-dihidropirimidin-5-carboxamidas N-sustituidas y de 2-(3,4-difluorobencil)-3-oxo-2,3-dihidro-1H-pirazol-4-carboxamidas N-sustituidas.

Info

Publication number
UY31984A
UY31984A UY0001031984A UY31984A UY31984A UY 31984 A UY31984 A UY 31984A UY 0001031984 A UY0001031984 A UY 0001031984A UY 31984 A UY31984 A UY 31984A UY 31984 A UY31984 A UY 31984A
Authority
UY
Uruguay
Prior art keywords
difluorobenzyl
carboxamides
oxo
substituted
dihydropyrimidin
Prior art date
Application number
UY0001031984A
Other languages
English (en)
Inventor
Stadtmueller Heinz
Engelhardt Harald
Boehmelt Guido
Kofink Christiane
Kuhn Daniel
Mcconnell Darryl
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of UY31984A publication Critical patent/UY31984A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención comprende compuestos de la fórmula general (1) en donde las unidades W, A, L, Qa y QH se defienen como en la reivindicación 1, que son apropiados para el tratamiento de enfermedades que se caracterizan por proliferación celular excesiva o anormal, así como su uso como medicamentos con las propiedades previamente mencionadas.
UY0001031984A 2008-07-16 2009-07-14 DERIVADOS DE 1-(3,4-difluorobencil)-6-oxo-1,6-dihidropirimidin-5-carboxamidas N-sustituidas y de 2-(3,4-difluorobencil)-3-oxo-2,3-dihidro-1H-pirazol-4-carboxamidas N-sustituidas. UY31984A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08160564 2008-07-16
EP09160839 2009-05-20

Publications (1)

Publication Number Publication Date
UY31984A true UY31984A (es) 2010-02-26

Family

ID=41401833

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001031984A UY31984A (es) 2008-07-16 2009-07-14 DERIVADOS DE 1-(3,4-difluorobencil)-6-oxo-1,6-dihidropirimidin-5-carboxamidas N-sustituidas y de 2-(3,4-difluorobencil)-3-oxo-2,3-dihidro-1H-pirazol-4-carboxamidas N-sustituidas.

Country Status (8)

Country Link
US (1) US20110313156A1 (es)
EP (1) EP2323986A2 (es)
JP (1) JP2011528025A (es)
AR (1) AR072751A1 (es)
CA (1) CA2729986A1 (es)
TW (1) TW201006838A (es)
UY (1) UY31984A (es)
WO (1) WO2010007114A2 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20110213A1 (es) 2008-07-29 2011-04-16 Boehringer Ingelheim Int Derivados de indolinona como inhibidores de quinasa
JP2012511000A (ja) * 2008-12-05 2012-05-17 メルク・シャープ・エンド・ドーム・コーポレイション ホスホイノシチド依存性キナーゼ１（ｐｄｋ１）の阻害剤
US8575203B2 (en) * 2010-04-21 2013-11-05 Boehringer Ingelheim International Gmbh Chemical compounds
CN102958927A (zh) * 2010-05-12 2013-03-06 Abbvie公司 激酶的吲唑抑制剂
JP5863058B2 (ja) * 2010-05-17 2016-02-16 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング １Ｈ−イミダゾ［４，５−ｃ］キノリン
US8680099B2 (en) * 2010-06-10 2014-03-25 Afraxis Holdings, Inc. 6-(ethynyl)pyrido[2,3-D]pyrimidin-7(8H)-ones for the treatment of CNS disorders
WO2012045195A1 (en) * 2010-10-09 2012-04-12 Abbott Laboratories Pyrrolopyrimidines as fak and alk inhibiters for treatment of cancers and other diseases
DE102010048374A1 (de) * 2010-10-13 2012-04-19 Merck Patent Gmbh Pyrrolidinone als MetAP-2 Inhibitoren
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN104662018B (zh) 2012-04-20 2017-10-24 阿迪维纳斯治疗有限公司 取代的杂双环化合物、组合物及其医疗应用
GEP201606598B (en) 2012-11-08 2017-01-10 Pfizer Heteroaromatic compounds as dopamine d1 ligands
CN103058934A (zh) * 2013-01-07 2013-04-24 盛世泰科生物医药技术(苏州)有限公司 一种5-乙酰基-2,4-二氯嘧啶的合成方法
WO2014175370A1 (ja) * 2013-04-25 2014-10-30 塩野義製薬株式会社 ピロリジン誘導体およびそれらを含有する医薬組成物
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
PL3052485T3 (pl) 2013-10-04 2022-02-28 Infinity Pharmaceuticals, Inc. Związki heterocykliczne i ich zastosowania
SG11201607705XA (en) 2014-03-19 2016-10-28 Infinity Pharmaceuticals Inc Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
CA2992945A1 (en) 2015-07-17 2017-01-26 Memorial Sloan-Kettering Cancer Center Combination therapy using pdk1 and pi3k inhibitors
US10160761B2 (en) 2015-09-14 2018-12-25 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
CN107226814A (zh) * 2016-03-23 2017-10-03 罗欣生物科技（上海）有限公司 一种巴瑞克替尼中间体的制备方法
CN105949196B (zh) * 2016-05-18 2018-06-29 南京富润凯德生物医药有限公司 一种mer/flt3双重抑制剂中间体的制备方法
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
AR117472A1 (es) 2018-12-21 2021-08-11 Celgene Corp Inhibidores de tienopiridina de ripk2
WO2020172197A1 (en) 2019-02-19 2020-08-27 Ultima Genomics, Inc. Linkers and methods for optical detection and sequencing
US11807851B1 (en) 2020-02-18 2023-11-07 Ultima Genomics, Inc. Modified polynucleotides and uses thereof
KR20230121758A (ko) 2020-11-18 2023-08-21 데시페라 파마슈티칼스, 엘엘씨. Gcn2 및 perk 키나제 억제제 및 그의 사용 방법
US20240239795A1 (en) * 2021-05-21 2024-07-18 Centre National De La Recherche Scientifique Novel azaindole derivatives as antiviral agents
WO2022243651A1 (fr) * 2021-05-21 2022-11-24 Centre National De La Recherche Scientifique (Cnrs) Nouveaux derives azaindole en tant qu'agents anticancereux
AU2022295990A1 (en) 2021-06-18 2024-01-04 Aligos Therapeutics, Inc. Methods and compositions for targeting pd-l1
TW202345806A (zh) 2022-03-31 2023-12-01 美商艾伯維有限公司 噻唑并〔５，４－ｂ〕吡啶ｍａｌｔ－１抑制劑

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL356984A1 (en) * 1998-08-20 2004-07-12 Agouron Pharmaceuticals, Inc. Non-peptide gnrh agents, methods and intermediates for their preparation
US7101878B1 (en) * 1998-08-20 2006-09-05 Agouron Pharmaceuticals, Inc. Non-peptide GNRH agents, methods and intermediates for their preparation
BR0312123A (pt) * 2002-06-13 2005-03-29 Pfizer Agentes de gnrh não peptìdicos, composições farmacêuticas e métodos para o seu uso
US20050288290A1 (en) * 2004-06-28 2005-12-29 Borzilleri Robert M Fused heterocyclic kinase inhibitors
US8778977B2 (en) * 2006-06-30 2014-07-15 Sunesis Pharmaceuticals, Inc. Pyridinonyl PDK1 inhibitors
CA2654670A1 (en) * 2006-07-06 2008-01-10 Boehringer Ingelheim International Gmbh New compounds
JP2010500336A (ja) * 2006-08-09 2010-01-07 ファイザー・プロダクツ・インク 炭酸脱水酵素阻害剤として有用な複素環
CA2690567A1 (en) * 2007-06-12 2008-12-18 Boehringer Ingelheim International Gmbh 3-hetrocyclylidene-indolinone derivatives as inhibitors of specific cell cycle kinases
WO2008156726A1 (en) * 2007-06-20 2008-12-24 Merck & Co., Inc. Inhibitors of janus kinases
BRPI0907963A2 (pt) * 2008-02-29 2015-08-04 Pfizer Derivados de indazola
ATE552255T1 (de) * 2008-06-05 2012-04-15 Glaxo Group Ltd 4-aminoindazole
EP2280946B1 (en) * 2008-06-05 2016-02-10 Glaxo Group Limited 4-carboxamide indazole derivatives useful as inhibitors of p13-kinases
JP5508400B2 (ja) * 2008-06-05 2014-05-28 グラクソ グループ リミテッド Ｐｉ３キナーゼの阻害剤としてのベンズピラゾール誘導体

Also Published As

Publication number Publication date
EP2323986A2 (en) 2011-05-25
WO2010007114A2 (en) 2010-01-21
AR072751A1 (es) 2010-09-15
WO2010007114A3 (en) 2010-03-11
US20110313156A1 (en) 2011-12-22
TW201006838A (en) 2010-02-16
CA2729986A1 (en) 2010-01-21
JP2011528025A (ja) 2011-11-10

Similar Documents

Publication Publication Date Title
UY31984A (es) DERIVADOS DE 1-(3,4-difluorobencil)-6-oxo-1,6-dihidropirimidin-5-carboxamidas N-sustituidas y de 2-(3,4-difluorobencil)-3-oxo-2,3-dihidro-1H-pirazol-4-carboxamidas N-sustituidas.
ECSP088932A (es) Nuevos compuestos químicos
BRPI0818672A2 (pt) 2'-fluor-2'-desoxitetra-hidrouridinas como inibidores da citidina desaminase
ECSP088905A (es) Nuevos compuestos
CO6640285A2 (es) 5-alquinil-pirimidinas
NI201000164A (es) Hidroximetil pirrolidinas como agonistas del receptor adrenérgico beta 3.
ECSP099823A (es) Nuevos compuestos químicos
CO6341617A2 (es) 5-alquinil-pirimidinas
ECSP088210A (es) Bencimidazoles sustituidos y métodos de preparación
GT200600081A (es) Derivados de acetilenno
UY31982A (es) Derivados de 1,2-dihidropiridin-3-carboxamidas n-sustituidas
ECSP099413A (es) COMPUESTOS A BASE DE 4 - fenil - 6 - (2,2,2 - trifluoro - 1 - feniletoxi)pirimidina Y MÉTODOS PARA SU EMPLEO
DOP2011000081A (es) Benzamida sustituida como ligandos del receptor de canabinoides
UY32859A (es) Compuestos y composiciones como inhibidores de cinasa de proteina
BRPI0814772A2 (pt) Indazóis substituídos por 5-piridinona
ECSP11010816A (es) Nuevos Compuestos
ECSP099675A (es) Compuestos heterocíclicos, composición y métodos de uso
MX2010006206A (es) Derivados de oxindol substituidos por 5-halogeno y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
UY31138A1 (es) Derivados de indolinonas sustituidas, composiciones conteniendolos y aplicaciones
CO6382123A2 (es) Antagonistas de la via hedgehog de ftalazina disustituida
CR11057A (es) Nuevos compuestos heterociclicos nitrogenados, su preparacion y su utilizacion como medicamentos antibacterianos
CO6341625A2 (es) Derivados de indol como agentes anticáncer
ECSP10010379A (es) Derivados de oxindol sustituido y su uso para el tratamiento de enfermedades dependientes de la vasopresina
CO6460762A2 (es) 5-alquinil-piridinas
UY31700A (es) Tiazolil-dihidro-indazoles

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20181108